Page 164 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 164
Chapter 6b
was 74% (95% CI, 69% to 79%) in the R-CHOP-14 arm versus 71% (95% CI, 66% to 76%) in the RR-CHOP-14 arm (HR, 1.20; 95% CI, 0.94 to 1.55; P = .15; adjusted for age group and age-adjusted IPI score; Fig 2B); the 5-year PFS rates were 69% (95% CI, 63% to 74%) and 64% (95% CI, 58% to 69%), respectively.
Among patients who had achieved CR on protocol treatment, the 3-year DFS rate from date of CR was 81% (95% CI, 76% to 85%) in the R-CHOP-14 arm versus 76% (95% CI, 70% to 81%) in the RR-CHOP-14 arm (HR, 1.24; 95% CI, 0.93 to 1.65; P = .15; adjusted for age group and age-adjusted IPI score; Fig 2C); the 5-year DFS rates were 75% (95% CI, 69% to 80%) and 70% (95% CI, 64% to 75%), respectively. OS at 3 years was 81% (95% CI, 76% to 85%) in the R-CHOP-14 arm versus 76% (95% CI, 70% to 80%) in the RR-CHOP-14 arm (HR, 1.27; 95% CI, 0.97 to 1.67; P = .09; adjusted for age group and age-adjusted
Fig. 2. Kaplan-Meier survival curves according to assigned treatment arm. (A) Failure-free survival (FFS), (B) progression-free survival (PFS), (C) disease-free survival (DFS) from complete remission, and (D) overall survival (OS).
All P values by Cox logistic regression (adjusted). D, death; F, no complete remission, relapse, or death; P, progression, relapse, or death; R, relapse or death; R-CHOP, rituximab on day 1 of each cycle plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm A); RR-CHOP, rituximab on day 1 and 8 of first 4 cycles and day 1 of remaining cycles plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm B).
162
